Management of steroid-dependent ulcerative colitis: immunomodulatory agents, biologics, or surgery?
Velayos
Fernando
F
Center for Colitis and Crohn's Disease, University of California, San Francisco, California 94118, USA. Fernando.velayos@ucsf.edu
Mahadevan
Uma
U
D000328:Adult; D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000601:surgery*; D039021:Colonic Pouches; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000069285:Infliximab; D015122:Mercaptopurine / Q000008:administration & dosage / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D016737:Proctocolectomy, Restorative; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D015122:Mercaptopurine; D001379:Azathioprine